Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression

Abstract

Introduction Real-world effectiveness trials suggest that antidepressant efficacy is limited in many patients with mood disorders, underscoring the urgent need for novel therapeutics to treat these disorders. Areas Covered Here, we review the clinical evidence supporting the use of novel modulators for the treatment of mood disorders, including specific glutamate modulators such as: 1) high-trapping glutamatergic modulators; 2) subunit (NR2B)-specific N-methyl-D-aspartate (NMDA) receptor antagonists; 3) NMDA receptor glycine-site partial agonists; and 4) metabotropic glutamate receptor (mGluR) modulators. We also discuss other promising, non-glutamatergic targets for potential rapid antidepressant effects in mood disorders, including the cholinergic system, the glucocorticoid system, and the inflammation pathway, as well as several additional targets of interest. Clinical evidence is emphasized, and non-pharmacological somatic treatments are not reviewed. In general, this paper only explores agents available in the United States. Expert Commentary Of these novel targets, the most promising—and the ones for whom the most evidence exists—appear to be the ionotropic glutamate receptors. However, moving forward will require us to fully embrace the goal of personalized medicine and will require health professionals to pre-emptively identify potential responders.

Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?

“…Additionally, these medications might take up to several weeks to induce pharmacological effects and patients often drop-off treatment because of a variety of unwanted secondary effects, which comprise insomnia, headache, sexual dysfunction, and dry mouth [38]. While novel therapeutic strategies are urgently needed for the management of MDD, PTSD, and other mood disorders, the nuclear receptors PPAR-α and γ are gaining consistent interest as new promising targets for treating behavioral dysfunction (please see Tables 1 and 2 for a summary) [39]. This is further substantiated by the recent discovery that stimulation of PPAR-α can enhance neurosteroid biosynthesis [10], which is implicated in the etiopathology of mood disorders and their treatment [7,[40][41][42][43].…”

Leptin in depression: a potential therapeutic target

“…Depression is a mood disorder with complicated etiopathogenesis, with different subtypes (or variable endophenotypes) which differ across individual patients. This complexity is in addition to such major divisions among mood disorders as MDD, bipolar disorder and seasonal affective disorder 58 , Gecici and colleagues first investigated the relationship between leptin and different clinical subtypes of MMD and found that depressive patients with atypical symptoms had higher serum leptin levels than controls 59 . No differences were found between depressive patients with a more typical profile and controls 59 .…”

International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets

“…On these bases, preventing hypercortisolemia has been recently considered as a novel pharmacological strategy for MDD and, in particular, for TRD (Henter et al, 2017). Mifepristone, a glucocorticoid receptor antagonist, seems to be efficacious in the treatment of TRD: Neurobiology and Identification of Novel Targets psychotic depression, a subtype of depression characterized by hypercortisolemia (Blasey et al, 2011), with a rapid improvement of depressive and psychotic symptoms (Belanoff et al, 2001(Belanoff et al, , 2002.…”